Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
Cullinan Therapeutics (Nasdaq: CGEM), a biopharmaceutical company specializing in modality-agnostic targeted therapies, has announced its participation in the upcoming Stifel 2025 Virtual Immunology and Inflammation Forum.
The company's Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will engage in a fireside chat on Tuesday, September 16, 2025, at 9:30 a.m. ET. Investors can access the webcast through Cullinan's investor relations website under the Events and Presentations section.
Cullinan Therapeutics (Nasdaq: CGEM), una società biofarmaceutica specializzata in terapie mirate agnostiche rispetto alla modalità, ha annunciato la partecipazione al prossimo Stifel 2025 Virtual Immunology and Inflammation Forum.
Il Direttore Medico, Jeffrey Jones, M.D., M.B.A., terrà una chiacchierata informale (fireside chat) il martedì 16 settembre 2025 alle 9:30 ora orientale. Gli investitori potranno seguire il webcast attraverso il sito di relazioni con gli investitori di Cullinan, nella sezione Eventi e Presentazioni.
Cullinan Therapeutics (Nasdaq: CGEM), una empresa biofarmacéutica especializada en terapias dirigidas que no dependen de la modalidad, ha anunciado su participación en el próximo Stifel 2025 Virtual Immunology and Inflammation Forum.
El Director Médico, Jeffrey Jones, M.D., M.B.A., participará en una charla informal el martes 16 de septiembre de 2025 a las 9:30 a. m. hora del Este. Los inversores pueden acceder al webcast a través del sitio de relaciones con inversores de Cullinan, en la sección Eventos y Presentaciones.
Cullinan Therapeutics (나스닥: CGEM)는 모달리티에 구애받지 않는 표적 치료제를 전문으로 하는 바이오제약 기업으로, 다가오는 Stifel 2025 Virtual Immunology and Inflammation Forum에 참여한다고 발표했습니다.
기업의 최고의료책임자(Chief Medical Officer), Jeffrey Jones, M.D., M.B.A.가 2025년 9월 16일 화요일 오전 9:30(Eastern Time)에 화롯가 대담(fireside chat)을 진행할 예정입니다. 투자자들은 Cullinan의 투자자 관계 웹사이트의 이벤트와 프레젠테이션 섹션에서 webcast를 이용할 수 있습니다.
Cullinan Therapeutics (Nasdaq: CGEM), une société biopharmaceutique spécialisée dans les thérapies ciblées indépendamment de la modality, a annoncé sa participation au prochain Forum virtuel Stifel 2025 Immunology and Inflammation.
Le directeur médical, Jeffrey Jones, M.D., M.B.A., participera à une conversation informelle le mardi 16 septembre 2025 à 9 h 30 (HE). Les investisseurs pourront accéder au webcast via le site des relations investisseurs de Cullinan, dans la section Événements et Présentations.
Cullinan Therapeutics (Nasdaq: CGEM), ein biopharmazeutisches Unternehmen, das sich auf modality-agnostic Targeted Therapies spezialisiert hat, hat seine Teilnahme am bevorstehenden Stifel 2025 Virtual Immunology and Inflammation Forum angekündigt.
Der Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., wird am Dienstag, dem 16. September 2025, um 9:30 Uhr Eastern Time an einem Fireside Chat teilnehmen. Investoren können den webcast über Cullinans Investor Relations-Website im Bereich Veranstaltungen und Präsentationen abrufen.
Cullinan Therapeutics (بورصة ناسداك: CGEM)، شركة أدوية بيولوجية تختص في العلاجات المستهدفة المستقلة عن النمط، أعلنت عن مشاركتها في منتدى Stifel 2025 الافتراضي للمناعة والالتهاب.
سيشارك الطبيب المدير التنفيذي الطبي، جيفري جونز، دكتور في الطب، وماجستير في إدارة الأعمال في الثلاثاء 16 سبتمبر 2025 الساعة 9:30 صباحًا بتوقيت شرق الولايات المتحدة في جلسة حوار حميم. يمكن للمستثمرين الوصول إلى البث عبر موقع علاقات المستثمرين الخاص بـ Cullinan ضمن قسم الأحداث والعروض التقديمية.
Cullinan Therapeutics (纳斯达克: CGEM)，一家专注于模式无关的靶向治疗的生物制药公司，宣布将参加即将举行的 Stifel 2025 虚拟免疫与炎症论坛。
公司的 首席医疗官 Jeffrey Jones 医学博士、工商管理硕士 将于 2025 年 9 月 16 日（星期二）美国东部时间上午 9:30 参加一场炉边谈话。投资者可以通过 Cullinan 的投资者关系网站在“活动与演示”部分访问网络直播。
- None.
- None.
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on Tuesday, September 16, 2025, at 9:30 a.m. ET.
A webcast of the fireside chat will be available under the Events and Presentations section of the Company’s investor relations website at https://investors.cullinantherapeutics.com/events.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company dedicated to creating new standards of care for patients. Cullinan has strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer. Cullinan’s portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of autoimmune and cancer indications. We push conventional boundaries from candidate selection to differentiated therapeutic, applying rigorous go/no go criteria at each stage of development to fast-track only the most promising molecules to the clinic and, ultimately, commercialization. With deep scientific expertise, our teams exercise creativity and urgency to deliver on our promise to bring new therapeutic solutions to patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow us on LinkedIn and X.
Contacts:
Investor Relations
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
FAQ
When is Cullinan Therapeutics (CGEM) presenting at the Stifel 2025 Virtual Immunology Forum?
Who will represent Cullinan Therapeutics (CGEM) at the Stifel 2025 Virtual Forum?
How can investors access Cullinan Therapeutics' (CGEM) presentation at the Stifel Forum?
What type of company is Cullinan Therapeutics (CGEM)?
